

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Oct 2021

Underlined items indicate changes from the previous announcement in Jul 2021.

XTANDI and Strategic products (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
enzalutamide MDV3100 (XTANDI)	Small molecule	Androgen receptor inhibitor	Metastatic castration-sensitive prostate cancer	China P-III	Pfizer	
			Non-metastatic castration-sensitive prostate cancer	P-III		
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Post-chemotherapy maintenance acute myeloid leukemia	P-III	In-house	
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-III		
			Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
			Acute myeloid leukemia in pediatric patients	P-III		
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Metastatic urothelial cancer, PD-1/PD-L1 inhibitor and platinum-containing chemotherapy pretreated	Europe Filed (Mar 2021)	In-house [Co-development with Seagen]	
			Metastatic urothelial cancer, progressed after anti-cancer medication	Japan <u>Approved (Sep 2021)</u>		
			Metastatic urothelial cancer, previously untreated (first line; combo with pembrolizumab)	P-III		
			Muscle-invasive bladder cancer (combo with pembrolizumab)	P-III		
			Other solid tumors	P-II		
			Non-muscle-invasive bladder cancer	P-I		

XTANDI and Strategic products (2/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
zolibetuximab IMAB362	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma	P-III	In-house (Ganymed)	
			Pancreatic adenocarcinoma	P-II		
roxadustat ASP1517/FG-4592 (EVRENZO)	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease	Europe <u>Approved (Aug 2021)</u>	FibroGen	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.
			Chemotherapy-induced anemia	P-II		
fezolinetant ESN364	Small molecule	NK3 receptor antagonist	Vasomotor symptoms associated with menopause	P-III	In-house (Ogeda)	
resamirigene bilparovvec AT132	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Jul 2021):

enzalutamide (MDV3100): Removed the description of the approval in Europe in Apr 2021 for metastatic hormone-sensitive prostate cancer.

enfortumab vedotin (ASG-22ME): Removed the description of the approval in US in Jul 2021 for metastatic urothelial cancer, cisplatin-ineligible and who have previously received one or more therapy. Obtained the approval in Japan in Sep 2021 for radically unresectable urothelial carcinoma that has progressed after anti-cancer chemotherapy.

roxadustat (ASP1517/FG-4592): Obtained the approval in Europe in Aug 2021 for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease.

Projects with Focus Area approach (1/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
Immuno-oncology	ASP1948/PTZ-329	Antibody	Anti-NRP1 antibody	Cancer	P-I	In-house (Potenza Therapeutics)	
	ASP1951/PTZ-522	Antibody	GITR agonistic antibody	Cancer	P-I	In-house (Potenza Therapeutics)	
	ASP9801	Oncolytic virus	Oncolytic virus carrying IL-7 and IL-12	Cancer	P-I	Tottori University [Discovered through collaborative research]	
	ASP7517	Cell therapy (artificial adjuvant vector cells)	WT1 loaded artificial adjuvant vector cell	Acute myeloid leukemia and myelodysplastic syndrome	P-II	RIKEN [Discovered through collaborative research]	
				Solid tumor	P-I		
	ASP0739	Cell therapy (artificial adjuvant vector cells)	NY-ESO-1 loaded artificial adjuvant vector cell	Cancer	P-I	RIKEN [Discovered through collaborative research]	
ASP1570	Small molecule		Cancer	P-I	In-house		
Blindness and Regeneration	ASP7317	Cell therapy	Retinal pigment epithelium cells	Geographic atrophy secondary to age-related macular degeneration, Stargardt disease	P-I	In-house (Ocata Therapeutics)	
Mitochondria Biology	ASP1128/MA-0217	Small molecule	PPAR δ modulator	Acute kidney injury	P-II	In-house (Mitobridge)	
	bocidelpar ASP0367/MA-0211	Small molecule	PPAR δ modulator	Primary mitochondrial myopathies	P-II	In-house (Mitobridge)	
Duchenne muscular dystrophy				P-I			

Projects with Focus Area approach (2/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
Genetic regulation	resamirigene bilparvovec AT132 ***	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
	AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-I	In-house (Audentes Therapeutics)	
(Other projects with Focus Area approach)	ASP3772	Next generation vaccine (MAPS technology)	Pneumococcal vaccine based on a multiple antigen-presenting system (MAPS) platform	Prevention of pneumococcal disease	P-II	Affinivax	
	FX-322	Small molecule	Inner ear progenitor cell activator (combination of GSK-3 inhibitor and HDAC inhibitor)	Sensorineural hearing loss	P-II	Frequency Therapeutics	Astellas has rights in Ex-US markets
	ASP0598	Recombinant protein	Recombinant human heparin-binding epidermal growth factor-like growth factor	Chronic tympanic membrane perforation	P-I	Auration Biotech	
	ASP2390	New generation vaccine (LAMP-Vax technology)		House dust mite-induced allergic rhinitis	P-I	Immunomic Therapeutics [Discovered through collaborative research]	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

*** AT132 is also listed in "XTANDI and Strategic products".

Updates from the previous announcement (Jul 2021):

ASP7517: Entered into Phase 2 for acute myeloid leukemia and myelodysplastic syndrome.

Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
mirabegron YM178	Small molecule	β_3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients	Europe P-III	In-house	
			Overactive bladder in pediatric patients	Europe P-III		
peficitinib ASP015K	Small molecule	JAK inhibitor	Rheumatoid arthritis	China P-III	In-house	
isavuconazole	Small molecule	Azole antifungal	Invasive aspergillosis and mucormycosis in pediatric patients	US P-II	Basilea	
ASP8062	Small molecule	GABA _B receptor positive allosteric modulator	Opioid use disorder	P-II	In-house	
			Alcohol use disorder	P-I		

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Update from the previous announcement (Jul 2021):

tacrolimus (FK506): Removed the description of the approval in US in Jul 2021 for prevention of organ rejection in adult and pediatric patients receiving lung transplantation.

ASP1617: Discontinued Phase 1 program for systemic lupus erythematosus.

Rx+ Program

As of Oct 2021

Underlined item indicates changes from the previous announcement in Jul 2021.

Sphere (Business area)	Program	Concept	Status *	Partner	Remarks
Chronic disease progression prevention	Game application for exercise support	Smartphone application to support exercise using motion sensing technology for people who needs regular exercise	Under development	BANDAI NAMCO Entertainment	
	Fit-eNce	Service to provide scientifically evidenced exercise programs and systems supporting regular exercise	Launched in limited areas		
	<u>Fit-eNce Home</u>	<u>Service to provide scientifically evidenced exercise programs and systems supporting regular exercise at home</u>	<u>Under test marketing</u>		
	BlueStar	Digital therapeutics for adults with diabetes	Under development	Welldoc	
	<u>EG Holter</u>	<u>Disposable Holter electrocardiography device</u>	Japan <u>Certified as a medical device (Aug 2021)</u>	<u>Nitto Denko M. Heart</u>	
Patient outcome maximization	ASP5354	Precision surgery-guide enabling identification of ureter in hysterectomy and colorectal surgery etc.	P-II		

* The list shows the most advanced stage if the stages are different depending on the region.

Updates from the previous announcement (Jul 2021)

Fit-eNce Home: Added as a new project

EG Holter: Added as a new project